Allakos 過去の業績
過去 基準チェック /06
Allakos's earnings have been declining at an average annual rate of -16.2%, while the Biotechs industry saw earnings growing at 19% annually.
主要情報
-16.2%
収益成長率
-5.8%
EPS成長率
| Biotechs 業界の成長 | 17.0% |
| 収益成長率 | n/a |
| 株主資本利益率 | -245.2% |
| ネット・マージン | n/a |
| 前回の決算情報 | 30 Jun 2024 |
最近の業績更新
更新なし
Recent updates
We Think Allakos (NASDAQ:ALLK) Needs To Drive Business Growth Carefully
Aug 27
We're Keeping An Eye On Allakos' (NASDAQ:ALLK) Cash Burn Rate
May 05We're Keeping An Eye On Allakos' (NASDAQ:ALLK) Cash Burn Rate
Dec 01Companies Like Allakos (NASDAQ:ALLK) Are In A Position To Invest In Growth
Aug 03Allakos (NASDAQ:ALLK) Will Have To Spend Its Cash Wisely
Apr 20Is Allakos Inc. (NASDAQ:ALLK) Expensive For A Reason? A Look At Its Intrinsic Value
Jan 04Allakos: Potential For Comeback With Lirentelimab With 2 Indications
Oct 18Allakos prices ~$150M underwritten offering
Sep 19Allakos falls as lead asset offers mixed results in late-stage trial
Sep 09Allakos (NASDAQ:ALLK) Will Have To Spend Its Cash Wisely
Aug 06Will Allakos (NASDAQ:ALLK) Spend Its Cash Wisely?
Apr 22Allakos: Sad End To A Promising Asset
Dec 23We're Hopeful That Allakos (NASDAQ:ALLK) Will Use Its Cash Wisely
Dec 01We Think Allakos (NASDAQ:ALLK) Can Afford To Drive Business Growth
Aug 16Allakos: Upcoming Phase 3 Data Makes The Stock Interesting
Aug 06Allakos provides lirentelimab clinical trial enrollment updates, names new CMO
Jun 07We're Hopeful That Allakos (NASDAQ:ALLK) Will Use Its Cash Wisely
May 02Have Allakos Inc. (NASDAQ:ALLK) Insiders Been Selling Their Stock?
Mar 10Allakos Inc. (NASDAQ:ALLK) Insiders Have Been Selling
Jan 28
We're Interested To See How Allakos (NASDAQ:ALLK) Uses Its Cash Hoard To Grow
Dec 07Allakos EPS misses by $0.02
Nov 09収支内訳
収支内訳
Allakos の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。
収益と収入の歴史
| 日付 | 収益 | 収益 | G+A経費 | 研究開発費 |
|---|---|---|---|---|
| 30 Jun 24 | 0 | -206 | 43 | 145 |
| 31 Mar 24 | 0 | -214 | 44 | 153 |
| 31 Dec 23 | 0 | -186 | 45 | 151 |
| 30 Sep 23 | 0 | -166 | 50 | 140 |
| 30 Jun 23 | 0 | -151 | 46 | 114 |
| 31 Mar 23 | 0 | -165 | 50 | 121 |
| 31 Dec 22 | 0 | -320 | 57 | 265 |
| 30 Sep 22 | 0 | -371 | 65 | 298 |
| 30 Jun 22 | 0 | -403 | 76 | 328 |
| 31 Mar 22 | 0 | -411 | 77 | 334 |
| 31 Dec 21 | 0 | -270 | 75 | 196 |
| 30 Sep 21 | 0 | -220 | 68 | 152 |
| 30 Jun 21 | 0 | -199 | 61 | 139 |
| 31 Mar 21 | 0 | -181 | 57 | 126 |
| 31 Dec 20 | 0 | -153 | 52 | 106 |
| 30 Sep 20 | 0 | -134 | 46 | 94 |
| 30 Jun 20 | 0 | -113 | 41 | 79 |
| 31 Mar 20 | 0 | -93 | 35 | 65 |
| 31 Dec 19 | 0 | -85 | 30 | 62 |
| 30 Sep 19 | 0 | -75 | 24 | 56 |
| 30 Jun 19 | 0 | -65 | 20 | 49 |
| 31 Mar 19 | 0 | -55 | 16 | 42 |
| 31 Dec 18 | 0 | -44 | 12 | 33 |
| 30 Sep 18 | 0 | -37 | 9 | 27 |
| 30 Jun 18 | 0 | -32 | 7 | 24 |
| 31 Mar 18 | 0 | -27 | 5 | 21 |
| 31 Dec 17 | 0 | -24 | 4 | 19 |
質の高い収益: ALLK is currently unprofitable.
利益率の向上: ALLK is currently unprofitable.
フリー・キャッシュフローと収益の比較
過去の収益成長分析
収益動向: ALLK is unprofitable, and losses have increased over the past 5 years at a rate of 16.2% per year.
成長の加速: Unable to compare ALLK's earnings growth over the past year to its 5-year average as it is currently unprofitable
収益対業界: ALLK is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).
株主資本利益率
高いROE: ALLK has a negative Return on Equity (-245.24%), as it is currently unprofitable.